UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549



FORM 10-QSB



[X]

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



For the quarterly period ended March 31, 2004



[__]

Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934



For the transition period to





Commission File Number

000-49833



ACRONGENOMICS INC.



(Exact name of small Business Issuer as specified in its charter)



NEVADA

52-2219285



(State or other jurisdiction of

(IRS Employer Identification No.)

incorporation or organization)





1530 9th Avenue, S.E.

Calgary, Alberta, Canada

T2G 0T7



(Address of principal executive offices)

(Zip Code)



Issuer=s telephone number, including area code:

(403) 693-8014





Cellway Ventures Inc.



(Former name, former address and former fiscal year, if changed since last report)



Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes    [__] No



State the number of shares outstanding of each of the issuer=s classes of common stock, as of the latest practicable date:  14,115,000 Shares of $0.001 par value Common Stock outstanding as of May 7, 2004.





Transitional Small Business Disclosure Format (check one): Yes  [   ]   No  [ X ]





PART I - FINANCIAL INFORMATION





ITEM 1.

FINANCIAL STATEMENTS.





2

























ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)





FINANCIAL STATEMENTS





MARCH 31, 2004 AND 2003

(Unaudited)

(Stated in U.S. Dollars)













ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



BALANCE SHEET

(Unaudited)

(Stated in U.S. Dollars)







|                                                                 |  
|---------------------------------------------------------------- | -
|                                                                 |  
|                                                                 |  
|ASSETS                                                           |  
|                                                                 |  
|Current                                                          |  
|Cash                                                             | $
|Prepaid expenses                                                 |  
|                                                                 |  
|                                                                 | $
|                                                                 |  
|LIABILITIES                                                      |  
|                                                                 |  
|Current                                                          |  
|Accounts payable                                                 | $
|Due to shareholder                                               |  
|                                                                 |  
|                                                                 |  
|SHAREHOLDERS EQUITY (DEFICIENCY)                                |  
|                                                                 |  
|Share Capital                                                    |  
|Authorized:                                                      |  
|100,000,000 common shares, par value with $0.001 per share       |  
|                                                                 |  
|Issued and outstanding:                                          |  
|10,115,000 common shares at March 31, 2004 and December 31, 2003 |  
|                                                                 |  
|Additional paid-in capital                                       |  
|                                                                 |  
|Deficit Accumulated During The Development Stage                 |  
|                                                                 |  
|                                                                 |  
|                                                                 | $

F-1











ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



STATEMENTS OF LOSS AND DEFICIT

(Unaudited)

(Stated in U.S. Dollars)







|                                                                      |                    |            | INCEPTION
|--------------------------------------------------------------------- | ------------------ | ---------- | ---------
|                                                                      |                    |            | AUGUST 17
|                                                                      | THREE MONTHS ENDED | 1999 TO   
|                                                                      | MARCH 31           | MARCH 31  
|                                                                      | 2004               | 2003       | 2004     
|                                                                      |                    |            |          
|Income                                                                |                    |            |          
|Advertising                                                           | $                  | -          | $        
|                                                                      |                    |            |          
|Expenses                                                              |                    |            |          
|Domain registration                                                   |                    | 142        |          
|Transfer agent/dues                                                   |                    | 3,365      |          
|Consulting fees                                                       |                    | 4,567      |          
|Professional fees                                                     |                    | 19,280     |          
|Travel                                                                |                    | 11,959     |          
|Bank charges/interest                                                 |                    | 109        |          
|Office and sundry                                                     |                    | 634        |          
|Website development                                                   |                    | -          |          
|                                                                      |                    | 40,056     |          
|                                                                      |                    |            |          
|Net Loss For The Period                                               |                    | 40,056     |          
|                                                                      |                    |            |          
|Deficit Accumulated During The Development Stage, Beginning Of Period |                    | 56,891     |          
|                                                                      |                    |            |          
|Deficit Accumulated During The Development Stage, End Of Period       | $                  | 96,947     | $        
|                                                                      |                    |            |          
|                                                                      |                    |            |          
|Net Loss Per Share, Basic and diluted                                 | $                  | 0.01       | $        
|                                                                      |                    |            |          
|                                                                      |                    |            |          
|Weighted Average Number Of Shares Outstanding                         |                    | 10,115,000 |          



F-2







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



STATEMENTS OF CASH FLOWS

(Unaudited)

(Stated in U.S. Dollars)







|                                                                           |                    |          | INCEPTION
|-------------------------------------------------------------------------- | ------------------ | -------- | ---------
|                                                                           |                    |          | AUGUST 17
|                                                                           | THREE MONTHS ENDED | 1999 TO 
|                                                                           | MARCH 31           | MARCH 31
|                                                                           | 2004               | 2003     | 2004     
|                                                                           |                    |          |          
|Cash Flows From Operating Activities                                       |                    |          |          
|Net loss for the period                                                    | $                  | (40,056) | $        
|                                                                           |                    |          |          
|Adjustments To Reconcile Net Loss To Net Cash Used By Operating Activities |                    |          |          
|Change in accounts payable                                                 |                    | (532)    |          
|Change in prepaid expenses                                                 |                    | 110      |          
|                                                                           |                    | (40,478) |          
|                                                                           |                    |          |          
|Cash Flows From Financing Activities                                       |                    |          |          
|Share capital                                                              |                    | -        |          
|Advances from shareholder                                                  |                    | 19,679   |          
|                                                                           |                    | 19,679   |          
|                                                                           |                    |          |          
|Increase (Decrease) In Cash                                                |                    | (20,799) |          
|                                                                           |                    |          |          
|Cash, Beginning Of Period                                                  |                    | 23,274   |          
|                                                                           |                    |          |          
|Cash, End Of Period                                                        | $                  | 2,475    | $        



F-3







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



STATEMENT OF STOCKHOLDERS EQUITY



MARCH 31, 2004

(Unaudited)

(Stated in U.S. Dollars)







|                                 | COMMON STOCK |        |           
|-------------------------------- | ------------ | ------ | ----------
|                                 |              |        | ADDITIONAL
|                                 |              |        | PAID-IN   
|                                 | SHARES       | AMOUNT | CAPITAL   
|                                 |              |        |           
|Shares issued for cash at $0.001 | 5,000,000    | $      | 5,000     
|Shares issued for cash at $0.01  | 5,000,000    |        | 5,000     
|Net loss for the period          | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 1999       | 10,000,000   |        | 10,000    
|                                 |              |        |           
|Shares issued for cash at $0.20  | 100,000      |        | 100       
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2000       | 10,100,000   |        | 10,100    
|                                 |              |        |           
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2001       | 10,100,000   |        | 10,100    
|                                 |              |        |           
|Shares issued for cash at $0.20  | 15,000       |        | 15        
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2002       | 10,115,000   |        | 10,115    
|                                 |              |        |           
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2003       | 10,115,000   |        | 10,115    
|                                 |              |        |           
|Net loss for the period          | -            |        | -         
|                                 |              |        |           
|Balance, March 31, 2004          | 10,115,000   | $      | 10,115    



F-4







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



NOTES TO FINANCIAL STATEMENTS



MARCH 31, 2004 AND 2003

(Unaudited)

(Stated in U.S. Dollars)







1.

BASIS OF PRESENTATION



The unaudited financial statements as of March 31, 2004 included herein have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted principles have been condensed or molded pursuant to such rules and regulations.  In the opinion of management, all adjustments (consisting or normal recurring accruals) considered necessary for a fair presentation have been included.  It is suggested that these financial statements be read in conjunction with the December 31, 2003 audited financial statements and notes thereto.



2.

NATURE OF OPERATIONS



a)

Organization



The Company was incorporated in the State of Nevada, U.S.A. on August 17, 1999.



b)

Development Stage Activities



The Company plans to acquire and commercialize proprietary technology in the bio-medial industry.  It plans to offer these products in Europe, Canada, the U.S. and other countries throughout the world.



The Company is in the development stage, therefore, recovery of its assets is dependent upon future events, the outcome of which is indeterminable.  In addition, successful completion of the Companys development program and its transition, ultimately to the attainment of profitable operations is dependent upon obtaining adequate financing to fulfill its development activities and achieve a level of sales adequate to support its cost structure.



c)

Going Concern



Since inception, the Company has suffered recurring losses and net cash outflows from operations.  The Company expects to continue to incur substantial losses to complete the development of its business.  Since its inception, the Company has funded operations through common stock issuances in order to meet its strategic objectives.  Management believes that sufficient funding will be available to meet its business objectives, including anticipated cash needs for working capital, and is currently evaluating several financing options.  However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of and, if successful, to commence the sale of its products under development.  As a result of the foregoing, there exists substantial doubt about the Companys ability to continue as a going concern.  These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

















F-5





3.

SIGNIFICANT ACCOUNTING POLICIES



The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States.  Because a precise determination of many assets and liabilities is dependent upon future events, the

preparation of financial statements for a period necessarily involves the use of estimates, which have been made using careful judgment.



The financial statements have, in managements opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below:



a)

Development Stage Company



The Company is a developed stage company as defined in the Statements of Financial Accounting Standards No. 7. The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced. All losses accumulated since inception have been considered as part of the Companys development stage activities.



b)

Use of Estimates



The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses for the reporting period.  Actual results could differ from these estimates.



c)

Income Taxes



The Company has adopted Statement of Financial Accounting Standards No. 109  Accounting for Income Taxes (SFAS 109).  This standard requires the use of an asset and liability approach for financial accounting and reporting on income taxes.  If it is more likely than not that some portion or all if a deferred tax asset will not be realized, a valuation allowance is recognized.



d)

Financial Instruments



The Companys financial instruments consist of cash, accounts payable and amounts due to shareholder.



Unless otherwise noted, it is managements opinion that this Company is not exposed to significant interest or credit risks arising from these financial instruments.  The fair value of these financial instruments approximate their carrying values, unless otherwise noted.



e)

Foreign Currency Translation



The Companys functional currency is the U.S. dollar.  Transactions in foreign currencies are converted to U.S. dollars at the rate of exchange prevailing at the time of the transactions.  Exchange gains and losses arising from the remeasurement of foreign currency-denominated assets and liabilities are included in income in the period in which they occur.



f)

Basic and Diluted Loss Per Share



In accordance with SFAS No. 128  Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding.  Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  At March 31, 2004, the Company has no stock equivalents that were anti-dilutive and excluded in the earnings per share computation.





F-6









4.

SUBSEQUENT EVENTS



Subsequent to March 31, 2004, the Company has signed an agreement with a European scientist to purchase certain patents and all associated rights to his highly predictive, metastic cancer molecular diagnostic test products in consideration of the issuance by the Company of 4,000,000 common shares.



Also subsequent to March 31, 2004, we received subscriptions in the aggregate amount of $420,000 of an equity financing which the Company anticipates will be in a total amount of $720,000.  In connection with such subscriptions, we will be issuing 420,000 units with each unit consisting of one (1) share of common stock, a purchase warrant to purchase one  (1) additional share of common stock for $1.00 per share and a second purchase warrant to purchase one (1) additional share of common stock for $1.20 per share.  Each warrant has a term of three years.



F-7



ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.



PLAN OF OPERATIONS



Our plan of operations for the next twelve months is to complete the following objectives within the time period specified, subject to our obtaining financing for the development of our business plan and operations:



(1) To close on one or more of the target companies or operations that we have identified; and



(2) To raise sufficient capital in order to operate target company(ies)



Although it is anticipated that we will utilize our common stock as a means of acquiring these target companies, we do anticipate raising $2,000,000 in order to maintain sufficient working capital for ongoing operations.



We therefore anticipate that we will be spending approximately $2,000,000 over the next twelve-month period pursuing this plan of operations. Of these anticipated expenditures, we anticipate that $1,000,000 will be spent on our plan of operations in the next six months. Our cash position was $2,475 as at March 31, 2004.



On April 16, 2004, we entered into an agreement with Dr. Letheris Georgakopoulos to acquire from him four (4) Greek patents and all associated know-how and intellectual property.  The patents cover highly predictive, metastic cancer molecular diagnostic test products, including one referred to as the EP-CAM Detection KitTM.



Acrongenomics Inc. plans in the next 2-3 months to complete the necessary filings for the CE Markings required for I.V.D (In Vitro Diagnostic) approval for the European Union of the Ep-CAM Detection Kit, and following that the submission of required documentation for FDA approval. The Company is currently in discussions with a number of diagnostic companies with a view of securing strategic alliances for the approval and commercialization of our product(s). Although no alliance has been contractually finalized we anticipate that due to the number of negotiations ongoing we will be able to finalize an alliance or alliances in the very near term. In our negotiations we are looking for a strategic partner to manufacture and market our first product. These negotiations could include the outright sale of our first product, sale of the rights inclusive of a royalty, or a joint venture. The Company is currently reviewing all options available in order to best enhance shareholder value. The market size for our first product is estimated to be in excess of $200 million dollars on an annual worldwide basis.



Results of Operations



We earned no revenues during the quarter year ended March 31, 2004 and earned no revenues during the same period from the previous year.  We do not anticipate earning revenues until such time as we close on an acquisition in accordance with our business plan and commence sales.  We are presently in the development stage and we can provide no assurance that we will be successful in completing any acquisitions or earning revenues from any acquisitions.



We incurred operating expenses in the amount of $40,056 for the quarter ended March 31, 2004, compared to operating expenses in the amount of $4,245 for the same period from the previous year. Operating expenses incurred during the quarter ended March 31, 2004 included professional fees in the amount of $19,280, paid primarily for legal and auditing services, $11,959 for travel, paid primarily for travel to Europe in connection with the acquisition described above and consulting fees of $4,567 paid for services of consultants that assisted in the acquisition.  We anticipate that our professional expenses will increase in 2004 as more personnel are hired to implement our business plan.



We incurred a loss of $40,056 for the quarter ended March 31, 2004 and a loss of $4,245 for the same period from the previous year. Our net losses were attributable entirely to our operating expenses.



We anticipate continuing operating losses in the foreseeable future.  We base this expectation in part on the fact that we will incur substantial operating expenses in completing our stated plan of operations before we will have the opportunity to earn revenues.

2



Financial Condition and Liquidity



We had cash of $2,475 as of March 31, 2004, compared to cash of $23,274 as of December 31, 2003.  We had a working capital deficiency of $17,204 as of March 31, 2004, compared to working capital of $21,109 as of December 31, 2003.



As discussed above under Plan of Operations, we anticipate that we will be spending approximately $2,000,000 over the next twelve-month period pursuing this plan of operations.  Of these anticipated expenditures, we anticipate that $1,000,000 will be spent on our plan of operations in the next six months.



As of May 11, 2004, we received subscriptions in the aggregate amount of $420,000 of a private equity financing which we anticipate will be for a total amount of $720,000.  We anticipate that our present cash reserves are sufficient for us to sustain our business operations for only the next four to five months.  We anticipate that we will require additional financing in the amount of $1,600,000 in order to pursue our business plan.  We anticipate that if we pursue any additional financing, the financing would be an equity financing achieved through the sale of our common stock.  We do not have any arrangement in place for any debt or equity financing.  If we are successful in completing an equity financing, existing shareholders will experience dilution of their interest in our company.  In the event we are not successful in obtaining such financing when necessary, we may not be able to proceed with our business plan.



ITEM 3.

CONTROLS AND PROCEDURES.



As required by Rule 13a-15 under the Securities Exchange Act of 1934 (the Exchange Act), we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2004, being the date of our most recently completed fiscal quarter.  This evaluation was carried out under the supervision and with the participation of Mr. W. Scott Lawler, who at the time was our Chief Executive Officer and Chief Financial Officer. On April 16, 2004, Mr. Lawler resigned as our Chief Executive Officer and Chief Financial Officer but remained a member of our Board of Directors. Also on April 16, 2004, Mr. Rick Walchuk became a member of our Board of Directors and was named our Chief Executive Officer and Chief Financial Officer. Based upon the aforementioned evaluation Mr. Lawler concluded that our internal control over financial reporting are effective in timely alerting management to material information relating to us required to be included in our periodic SEC filings.  There have been no significant changes in our internal control over financial reporting or in other factors that have materially affected or is reasonably likely to materially affect our internal control over financial reporting.



Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

3





During our most recently completed fiscal quarter ended March 31, 2004, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to affect, our internal control over financial reporting.



The term internal control over financial reporting is defined as a process designed by, or under the supervision of, the registrant's principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:



Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;



Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant;and



Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant's assets that could have a material effect on the financial statements.







4



PART II--OTHER INFORMATION



ITEM 1.

LEGAL PROCEEDINGS



We are not a party to any material legal proceedings and to our knowledge, no such proceedings are threatened or contemplated.



ITEM 2.

CHANGES IN SECURITIES AND USE OF PROCEEDS



We did not complete any unregistered sales of our common stock during our fiscal quarter ended March 31, 2004.



On May 7, 2004, we issued 4 million restricted shares of our common stock to one of our directors, Dr. Leftheris Georgakopoulos, in consideration of his transfer of four (4) Greek patents, intellectual property and associated know-how to the Acrongenomics.



On May 11, 2004, we accepted subscriptions totaling $420,000, for which we will be issuing 420,000 units, with each individual unit consisting of one (1) share of our common stock, a purchase warrant to purchase one (1) additional share of common stock for $1.00 and a second purchase warrant to purchase one (1) additional share of common stock for $1.20.  Each warrant has a term of three (3) years.



The sale of securities described in the two (2) immediately preceding paragraphs were each exempt from registration due to the exemptions found in Regulation S (Reg. S), promulgated by the Securities and Exchange Commission under the Securities Act of 1933. Acrongenomics paid no commissions in connection with the acquisition of the patents and issuance of four (4) million shares but will pay a finders fee in the form of 400,000 restricted shares of common stock to the shares issued for the patents.  Acrongenomics will pay a commission of $42,000 on the sale of the units for $420,000 and also a finders fee of 42,000 shares of common stock.All of these securities were issued in offshore transactions since the offerees were not in the United States and the purchasers were outside the United States at the time of the purchase. Moreover, there were no directed selling efforts of any kind made in the United States. All documents used in connection with the offers and sales of the securities offshore included statements to the effect that the securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless the securities are registered under the Act or an exemption there from is available and that no hedging transactions involving those securities may not be conducted unless in compliance with the Act. Each offshore subscriber certified that he or it is not a U.S. person and is not acquiring the securities for the account or benefit of any U.S. person and agreed to resell such securities only in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an available exemption from registration. The securities sold are restricted securities and the certificates representing these shares have been affixed with a standard restrictive legend, which states that the securities cannot be sold without registration under the Securities Act of 1933 or an exemption there from and the Company is required to refuse to register any transfer that does not comply with such requirements.



ITEM 3.

DEFAULTS UPON SENIOR SECURITIES



None.



ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to our security holders for a vote during the fiscal quarter ended March 31, 2004.



ITEM 5.

OTHER INFORMATION.



On April 16, 2004, Mr. Rick Walchuk was appointed to the Companys Board of Directors and also named as the Companys Chief Executive Officer.  On such date, the Company also appointed Dr.Leftheris Georgakopoulos to the Board of Directors and named as President.  Dr. Georgakopoulos is the scientist

5



from whom the Company acquired the patents referred to above under PART I - ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION  PLAN OF OPERATIONS.



ITEM 6.

EXHIBITS AND REPORTS ON FORM 8-K





(a)

EXHIBITS REQUIRED BY ITEM 601 OF FORM 8-K





|Exhibit Number | Description of Exhibit                                                                 
|-------------- | ---------------------------------------------------------------------------------------
|3.1            | Articles of Incorporation (1)                                                          
|3.2            | Bylaws, as amended (1)                                                                 
|4.1            | Share Certificate (1)                                                                  
|31.1           | Rule 13a-14(a) Certification of Chief Executive Officer and Chief Financial Officer (2)
|32.1           | Section 1350 Certification of Chief Executive Officer and Chief Financial Officer (2)  



(1) Previously filed with the Securities and Exchange Commission as an exhibit to the Registrants Form 10-SB originally filed May 24, 2002, as amended.



(2)  Filed as an Exhibit to this Quarterly Report on Form 10-QSB.



(b)  REPORTS ON FORM 8-K



We did not file any Current Reports on Form 8-K during the fiscal quarter ended March 31, 2004 and we have not filed any Current Reports on Form 8-K since March 31, 2004.



SIGNATURES



In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



ACRONGENOMICS, INC.



Date:

May 12, 2004





By: /s/ Rick Walchuk

Name:

RICK WALCHUK

Title:

Chief Executive Officer and Chief Financial Officer



6